Rep. Ocasio-Cortez slams Gilead over HIV drug prices

Rep. Alexandria Ocasio-Cortez, D-N.Y., didn't hold back Thursday in questioning the chief executive of the company that makes Truvada about the high cost of the drug used to prevent HIV with pre-exposure prophylaxis, or PrEP.

"The list price is almost $2,000 in the United States. Why is it $8 in Australia?" Ocasio-Cortez asked the CEO of Gilead Sciences, Daniel O'Day, after noting the company made $3 billion in revenue off the once-a-day pill in 2018.

O'Day responded that "Truvada still has patent protection in the United States, and in the rest of the world it is generic." He noted that, as announced last week, the drug is set to be generically available in the U.S. in September 2020.

"There's no reason this should be $2,000 a month," Ocasio-Cortez, who has pushed for the hearing before the House Committee on Oversight and Reform. "People are dying because of it, and there's no enforceable reason for it."

RELATED: Former drug company executive Martin Shkreli

16 PHOTOS
Former drug company executive Martin Shkreli
See Gallery
Former drug company executive Martin Shkreli
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., June 26, 2017. REUTERS/Lucas Jackson
Martin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, center, and attorney Evan Greebel, left, exit federal court in New York, U.S., on Thursday, Dec. 17, 2015. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. Greebel is accused of conspiring with Shkreli in part of the scheme. Photographer: Peter Foley/Bloomberg via Getty Images
Martin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, exits federal court in New York, U.S., on Thursday, Dec. 17, 2015. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. Photographer: Peter Foley/Bloomberg via Getty Images
Martin Shkreli, chief investment officer of MSMB Capital Management, sits for a photograph in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, works on a computer in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, sits behind a chess board in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli (L), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives for a hearing at U.S. Federal Court in Brooklyn, New York, U.S. October 14, 2016. REUTERS/Lucas Jackson
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs following a hearing at U.S. Federal Court in Brooklyn, New York, U.S., April 26, 2017. REUTERS/Brendan McDermid
Martin Shkreli (C), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives for a hearing at U.S. Federal Court in Brooklyn, New York, U.S. October 14, 2016. REUTERS/Lucas Jackson
Martin Shkreli (C), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives at a U.S. Federal Court in New York, U.S., June 6, 2016. REUTERS/Lucas Jackson
Former drug executive Martin Shkreli exits the U.S. Federal Courthouse in the Brooklyn borough of New York February 3, 2016. REUTERS/Brendan McDermid
Martin Shkreli (top, R), former CEO of Turing Pharmaceuticals LLC, arrives before a House Oversight and Government Reform hearing on "Developments in the Prescription Drug Market Oversight" on Capitol Hill in Washington February 4, 2016. REUTERS/Joshua Roberts
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, right, exits federal court with his attorney Benjamin Brafman in the Brooklyn borough of New York, U.S., on Thursday, June 29, 2017. Shkreli is accused of engineering separate frauds tied to his control of two hedge funds he ran as well as�Retrophin Inc., a pharmaceutical company he founded in 2011. Photographer: Peter Foley/Bloomberg via Getty Images
Martin Shkreli (C), chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York December 17, 2015. REUTERS/Lucas Jackson
Bloomberg Best of the Year 2016: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals LLC, reacts during a House Committee on Oversight and Government Reform hearing on prescription drug prices in Washington, D.C., U.S., on Thursday, Feb. 4, 2016. Shkreli, who is no longer with Turing and faces federal fraud charges unrelated to the drugmaker, declined to make any comments to the committee. 'On the advice of counsel, I invoke my Fifth Amendment,' Shkreli said. Photographer: Pete Marovich/Bloomberg via Getty Images
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals LLC, smiles during a House Committee on Oversight and Government Reform hearing on prescription drug prices in Washington, D.C., U.S., on Thursday, Feb. 4, 2016. Shkreli, who is no longer with Turing and faces federal fraud charges unrelated to the drugmaker, declined to make any comments to the committee. 'On the advice of counsel, I invoke my Fifth Amendment,' Shkreli said. Photographer: Pete Marovich/Bloomberg via Getty Images
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

Ocasio-Cortez also claimed, as has been alleged by activists and academics, that Truvada's use as an HIV prevention pill was discovered by the U.S. government.

"We the public, we the people, developed this drug, we paid for this drug, we lead and developed all the grounding patents to create PrEP, and then that patent has been privatized despite the fact that the patent is owned by the public, who refused to enforce it," Ocasio-Cortez said.

In prepared remarks, O'Day denied the charge that the Centers for Disease Control and Prevention, part of the Department of Health and Human Services, owns the patent for PrEP. "Every single Gilead employee is proud that we invented Truvada, a medicine that can both treat and prevent HIV," he said.

"Our well-supported view is that the U.S. government does not hold valid patents on the use of Truvada for pre-exposure prophylaxis, nor does it hold any patent for Truvada itself," O'Day added.

The hearing came as activists have ramped up pressure against Gilead, a company that commercializes and manufactures a variety of therapies and cures for chronic diseases.

Members of the PrEP4All Collaboration, a group of activists pushing for broad PrEP access, and legal experts filed a class action lawsuit on Tuesday alleging that the nation's largest HIV drug manufacturers, including Gilead, for years conspired to keep cheaper generic component medications out of popular "combination pills" that make treating HIV as simple as taking one pill a day.

Read Full Story